摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-ethyl-2,2-dimethyl-3H-1,4-benzoxazine

中文名称
——
中文别名
——
英文名称
4-ethyl-2,2-dimethyl-3H-1,4-benzoxazine
英文别名
——
4-ethyl-2,2-dimethyl-3H-1,4-benzoxazine化学式
CAS
——
化学式
C12H17NO
mdl
——
分子量
191.27
InChiKey
TVNCWUZTAGXUNF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    12.5
  • 氢给体数:
    0
  • 氢受体数:
    2

文献信息

  • MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS
    申请人:Simmen Kenneth Alan
    公开号:US20090247512A1
    公开(公告)日:2009-10-01
    Inhibitors of HCV replication of formula (I) and the N-oxides, salts, or stereoisomers thereof, wherein each dashed line represents an optional double bond; X is N, CH and where X bears a double bond it is C; R 1 is —OR 6 , —NH—SO 2 R 7 ; R 2 is hydrogen, and where X is C or CH, R 2 may also be C 1-6 alkyl; R 3 is hydrogen, C 1-6 alkyl, C 1-6 alkoxyC 1-6 alkyl, or C 3-7 cycloalkyl; n is 3, 4, 5, or 6; R 4 and R 5 taken together with the nitrogen atom to which they are attached form a bicyclic ring system selected from wherein said ring system may optionally be substituted with 1-3 substituents; R 6 is hydrogen; aryl; Het; C 3-7 cycloalkyl optionally substituted with C 1-6 alkyl; or C 1-6 alkyl optionally substituted with C 3-7 cycloalkyl, aryl or with Het; R 7 is aryl; Het; C 3-7 cycloalkyl optionally substituted with C 1-6 alkyl; or C 1-6 alkyl optionally substituted with C 3-7 cycloalkyl, aryl or with Het; aryl is phenyl or naphthyl, each of which may be optionally substituted with 1-3 substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms each independently selected from N, O or S, and being optionally substituted with 1-3 substituents pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.
    HCV复制抑制剂的公式(I)及其N-氧化物,盐或立体异构体,其中每个虚线表示可选的双键;X为N,CH,其中X带有双键时为C;R1为—OR6,—NH—SO2R7;R2为氢,其中X为C或CH时,R2也可以是C1-6烷基;R3为氢,C1-6烷基,C1-6烷氧基C1-6烷基或C3-7环烷基;n为3、4、5或6;R4和R5与它们所连接的氮原子共同形成选自下列的双环系统,其中所述环系统可以选择性地被1-3个取代基取代;R6为氢;芳基;Het;C3-7环烷基,可选地取代C1-6烷基;或C1-6烷基,可选地取代C3-7环烷基,芳基或与Het取代基;R7为芳基;Het;C3-7环烷基,可选地取代C1-6烷基;或C1-6烷基,可选地取代C3-7环烷基,芳基或与Het取代基;芳基为苯基或基,每个都可以选择性地被1-3个取代基取代;Het是一个含有1-4个杂原子的5或6元饱和、部分不饱和或完全不饱和的杂环,每个杂原子独立地选自N、O或S,并且可以选择性地被1-3个取代基取代。本发明还提供含有化合物(I)的制药组合物和制备化合物(I)的方法。公式(I)的HCV抑制剂利托那韦生物利用度组合也提供。
  • N-LINKED HETEROCYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS
    申请人:Qiao Jennifer
    公开号:US20100197716A1
    公开(公告)日:2010-08-05
    The present invention provides novel ureas containing N-aryl or N-heteroaryl substituted heterocycles of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, B, D and W are as defined herein. These compounds are selective inhibitors of the human P2Y 1 receptor which can be used as medicaments.
    本发明提供了一种新型尿素,包含式(I)中的N-芳基或N-杂环芳基取代的杂环,或其立体异构体、互变异构体、药学上可接受的盐或溶剂形式,其中变量A、B、D和W如本文所定义。这些化合物是人类P2Y1受体的选择性抑制剂,可用作药物。
  • US7550499B2
    申请人:——
    公开号:US7550499B2
    公开(公告)日:2009-06-23
  • US7728008B2
    申请人:——
    公开号:US7728008B2
    公开(公告)日:2010-06-01
  • US8329718B2
    申请人:——
    公开号:US8329718B2
    公开(公告)日:2012-12-11
查看更多